Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
H. Yu, H. Nishio, J. Barbi, M. Mitchell-Flack, P. D. A. Vignali, Y. Zheng, A. Lebid, K.-Y. Chang, J. Fu, M. Higgins, C.-T. Huang, X. Zhang, Z. Li, L. Blosser, A. Tam, , D. M. Pardoll
This study shows that neuritin modulates T cell electrical and metabolic states, influencing immune tolerance and immunity.
bioRxiv · Jan 31, 2024Immunology
C. R. Ager, M. Zhang, M. Chaimowitz, S. Bansal, A. Obradovic, M. Rogava, J. C. Melms, P. McCann, C. Spina, C. G. Drake, M. C. Dallos, B. Izar
The paper identifies KLRG1-expressing CD4 T cell subsets linked to tumor progression and immunotherapy response using longitudinal flow cytometry and machine learning.
bioRxiv · Jan 1, 2023Immunology
J. E. Hawley, A. Z. Obradovic, M. C. Dallos, E. A. Lim, K. Runcie, C. R. Ager, J. M. McKiernan, C. B. Anderson, G. J. Decastro, J. L. Weintraub, R. K. Virk, I. Lowy, J. Hu, M. G. Chaimowitz, X. V. Guo, , C. G. Drake
The paper analyzes single-cell RNAseq data from metastatic castration-sensitive prostate cancer patients treated with anti-PD-1 immunotherapy, showing increased immune infiltrate and identifying therapy-resistant tumor subpopulations and druggable targets.
bioRxiv · May 6, 2022 · PreprintCancer Biology
A. Obradovic, L. Tomassoni, D. Yu, K. Guillan, K. Souto, E. Fraser, S. Bates, C. G. Drake, Y. Saenger, F. D. Cruz, A. Kung, A. Califano
The paper develops a single-cell framework to prioritize drugs for cholangiocarcinoma by analyzing subpopulations and validating predictions in patient-derived xenografts.
bioRxiv · Feb 28, 2022 · PreprintCancer Biology
Z. A. Lopez-Bujanda, M. C. Haffner, M. G. Chaimowitz, N. Chowdhury, N. J. Venturini, A. Obradovic, C. S. Hansen, J. Jackow, K. S. Sfanos, C. J. Bieberich, P. J. Hurley, M. J. Selby, A. J. Korman, A. M. Christiano, A. M. De Marzo, C. G. Drake
This study identifies IL-8 secretion from prostate cancer cells during castration as a driver of myeloid infiltration and cancer progression, suggesting targeting IL-8/CXCR2 with immunotherapy could delay castration resistance.
bioRxiv · May 27, 2019Immunology